JP4237703B2 - インスリン様成長因子結合タンパク質−４及びポリ（エチレングリコール）の接合体 - Google Patents

インスリン様成長因子結合タンパク質−４及びポリ（エチレングリコール）の接合体 Download PDF

Info

Publication number
JP4237703B2
JP4237703B2 JP2004539015A JP2004539015A JP4237703B2 JP 4237703 B2 JP4237703 B2 JP 4237703B2 JP 2004539015 A JP2004539015 A JP 2004539015A JP 2004539015 A JP2004539015 A JP 2004539015A JP 4237703 B2 JP4237703 B2 JP 4237703B2
Authority
JP
Japan
Prior art keywords
igfbp
peg
kda
pegylated
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004539015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503843A (ja
Inventor
ラング，クルト
シャウプマー，アンドレス
シューマッハー，ラルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2006503843A publication Critical patent/JP2006503843A/ja
Application granted granted Critical
Publication of JP4237703B2 publication Critical patent/JP4237703B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004539015A 2002-09-27 2003-09-25 インスリン様成長因子結合タンパク質−４及びポリ（エチレングリコール）の接合体 Expired - Fee Related JP4237703B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021844 2002-09-27
PCT/EP2003/010658 WO2004028568A1 (en) 2002-09-27 2003-09-25 Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)

Publications (2)

Publication Number Publication Date
JP2006503843A JP2006503843A (ja) 2006-02-02
JP4237703B2 true JP4237703B2 (ja) 2009-03-11

Family

ID=32039114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004539015A Expired - Fee Related JP4237703B2 (ja) 2002-09-27 2003-09-25 インスリン様成長因子結合タンパク質−４及びポリ（エチレングリコール）の接合体

Country Status (9)

Country Link
US (1) US20060100144A1 (de)
EP (1) EP1545623B1 (de)
JP (1) JP4237703B2 (de)
AT (1) ATE361761T1 (de)
AU (1) AU2003285286A1 (de)
CA (1) CA2498062C (de)
DE (1) DE60313786T2 (de)
ES (1) ES2285215T3 (de)
WO (1) WO2004028568A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028302A1 (en) * 2004-09-27 2010-02-04 Ludwig-Maximilians- Universität München Use of IGFBP-2 in Senescence Diseases and for the Maintenance of Organ Functions
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
JP2011507801A (ja) 2007-09-11 2011-03-10 ユニバーシティ オブ マサチューセッツ 癌の処置のためのインスリン様成長因子結合タンパク質７
WO2011003780A1 (en) 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
US20130041134A1 (en) * 2009-11-05 2013-02-14 Sangart ,Inc. Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material
CA2822481A1 (en) 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
WO2013040504A2 (en) 2011-09-14 2013-03-21 University Of Massachusetts Srpx for treatment of cancer
MX387205B (es) * 2014-08-19 2025-03-18 Biogen Ma Inc Método de pegilación.
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
WO2016196017A1 (en) 2015-06-04 2016-12-08 Antriabio, Inc. Amine pegylation methods for the preparation of site-specific protein conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004775A (en) * 1990-08-03 1999-12-21 The Salk Institute For Biological Studies DNA encoding IGFBP-4
US5212074A (en) * 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6841386B2 (en) * 2001-04-10 2005-01-11 Viacell, Inc. Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
CA2449290A1 (en) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Mutants of igf binding proteins and methods of production of antagonists thereof

Also Published As

Publication number Publication date
DE60313786T2 (de) 2008-01-24
ATE361761T1 (de) 2007-06-15
AU2003285286A1 (en) 2004-04-19
WO2004028568A1 (en) 2004-04-08
JP2006503843A (ja) 2006-02-02
EP1545623A1 (de) 2005-06-29
CA2498062A1 (en) 2004-04-08
ES2285215T3 (es) 2007-11-16
CA2498062C (en) 2010-05-25
US20060100144A1 (en) 2006-05-11
DE60313786D1 (de) 2007-06-21
EP1545623B1 (de) 2007-05-09

Similar Documents

Publication Publication Date Title
KR101022577B1 (ko) 항원성이 감소한 중합체 콘쥬게이트, 이의 제조방법 및용도
JP5336372B2 (ja) Ｇ−ｃｓｆ部位特異的モノコンジュゲート
AU2021258008A1 (en) Conjugates of an IL-15 moiety and a polymer
AU2016228555B2 (en) Conjugates of an IL-7 moiety and a polymer
JP2006321808A (ja) 化学的に修飾されたヒト成長ホルモンコンジュゲート
JP2012067100A (ja) Ｉｌ−２１の誘導体
JP2012116840A (ja) タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法
JP2006516263A (ja) 化学修飾されたヒト成長ホルモンコンジュゲート
US20120128629A1 (en) Method of labelling interferons with peg
JP2017205120A (ja) コリンエステラーゼ部分とポリマーとのコンジュゲート
KR20220097921A (ko) 인터루킨-22의 치료 유도체
JP4237703B2 (ja) インスリン様成長因子結合タンパク質−４及びポリ（エチレングリコール）の接合体
JP2011507913A (ja) Ｙ型ポリエチレングリコール修飾したｇ−ｃｓｆならびにその製造方法および使用
EP1673387A1 (de) Il-21-derivate
EA006368B1 (ru) Химически модифицированные конъюгаты прогенипоэтина
JP2007522198A (ja) 化学修飾されたヒト成長ホルモン受容体アンタゴニスト結合体
JP2005526505A (ja) ヒトゲラチナーゼａのｃドメイン及びポリエチレングリコールの接合体、その精製方法及び使用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080321

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081118

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081218

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111226

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees